Profile photo Zsolt Sebestyen

Zsolt Sebestyen

Associate Professor

Biography

Obtained his PhD in Hungary at University of Debrecen, where he became fascinated by biophysical techniques that he learned to use to study molecular interactions in living cells. He was further trained in the Babraham Institute In Cambridge (UK) and later at the ErasmusMC in Rotterdam (NL) where he as postdoctoral fellow has studied the molecular needs of genetic engineering of T cells for the immunotherapy of cancer. He continued his career at the UMCU in Utrecht, where he was appointed in 2014 as staff member of Section Applied within the Laboratory of Translational Immunology. He is currently focusing on the developement of novel gamma delta T cell-based immunotherapies and the better understanding of innate T cell and tumour cell interactions.  Reserach interest:  Tumour recognition of innate immune cells, Immune receptors , Genetic engineering.

Research groups

Tumor Immunology

Research aim

Our research aims to revolutionise cancer treatment by advancing innovative immunotherapies, ensuring safer, more effective therapies, and improving patient outcomes, ultimately transforming lives through cutting-edge translational cancer research.

Go to group

Recent publications

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies Ulrike Weirauch, Markus Kreuz, Colin Birkenbihl, Miriam Alb, Maria Quaranta, Laurence Calzone, Sophia Orozco-Ruiz, Stefanie Binder, Luise Fischer, Solène Clavreul, Morine Maguri, Maximilian Ferle, Michael Rade, Guillaume Azarias, Jay R Hydren, Jakub Jamarik, Daniel Schwarz, Zsolt Sebestyen, Jurgen Kuball, Georg Popp, Chloé Antoine, Manon Knockaert, Clara T Schoeder, David Fandrei, Carmen Sanges, Vaclovas Radvilas, Nico Gagelmann, Markus Rückert, Olaf Penack, Stephan Fricke, Andreas Schmidt, Carol Ward, Carl Steinbeisser, Jean-Marc Van Gyseghem, Anna Niarakis, Laurent Garderet, Michael Hudecek, Thomas Neumuth, Uwe Platzbecker, Ulrike Köhl, Regina Demlova, Andreas Kremer, Stefan Franke, Holger Fröhlich, Maximilian Merz, Kristin Reiche,
NPJ DIGITAL MEDICINE, 2025, vol. 8
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy Dennis X Beringer, Trudy Straetemans, Susana Minguet, Caterina Riillo, Lydia Lynch, Zsolt Sebestyen, Jürgen Kuball
Nature Reviews Cancer, 2025, vol. 25, p.590-612
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation Thomas Kimman, Marta Cuenca, Ralph G Tieland, Dedeke Rockx-Brouwer, Jasmijn Janssen, Benjamin Motais, Anne Slomp, Corine Pleijte, Sabine Heijhuurs, Angelo D Meringa, Wendy Boschloo, Douwe Mt Bosma, Sanne Kroos, Vania Lo Presti, Joost P G Sluijter, Stefan Nierkens, Niels Bovenschen, Jürgen Kuball, Alain van Mil, Monique C Minnema, Zsolt Sebestyén, Victor Peperzak
Nature Communications, 2025, vol. 16
CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy Darja Marolt Presen, Duško Lainšček, Jane Kinghorn, Zsolt Sebestyen, Jurgen Kuball, Leila Amini, Petra Reinke, Anke Fuchs, Roman Jerala, Mojca Benčina
Computational and Structural Biotechnology Journal, 2025, vol. 27, p.10-16
BEHAV3D Maria Alieva, Mario Barrera Román, Sam de Blank, Diana Petcu, Amber L. Zeeman, Noël M.M. Dautzenberg, Annelisa M. Cornel, Cesca van de Ven, Rob Pieters, Monique L. den Boer, Stefan Nierkens, Friso G.J. Calkoen, Hans Clevers, Jürgen Kuball, Zsolt Sebestyén, Ellen J. Wehrens, Johanna F. Dekkers, Anne C. Rios
Nature protocols, 2024, vol. 19, p.2052-2084
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML Vania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens
Journal for ImmunoTherapy of Cancer, 2024, vol. 12